SYS-CON MEDIA Authors: Bob Gourley, Sandi Mappic, Eric Brown, RealWire News Distribution, Kevin Benedict

News Feed Item

Leading Biotechnology Company Selects OmniComm Systems'(R) TrialMaster(R)

TrialMaster to Be Utilized for Multiple Phase III Clinical Trials

FORT LAUDERDALE, FL -- (Marketwired) -- 07/07/14 -- OmniComm Systems, Inc. (OTCQB: OMCM), a leading global provider of data management solutions for clinical trials, today announced that a leading biotechnology company, selected OmniComm's TrialMaster electronic data capture technology (EDC) to support three Phase III late stage clinical development studies. TrialMaster will be used for an open-labeled, multicenter, safety study and two randomized, double-blind, placebo-controlled efficacy and safety studies. OmniComm's proven technology and processes for integrating TrialMaster with other best-of-breed solutions was an important factor in selecting TrialMaster as their preferred EDC system. This leading biotechnology company will integrate TrialMaster with its preferred Interactive Response Technologies (IRT) solution. IRT solutions automate randomization and clinical supplies management and when integrated with TrialMaster EDC provides a comprehensive end-to-end solution.

TrialMaster's intuitive user interface and innovative data capture, data management and reporting functionality was a significant factor in this company's selection of TrialMaster. TrialMaster also includes embedded eLearning, allowing researchers to easily learn the system and quickly and accurately initiate new clinical trials.

"This award is not only about choosing the best EDC system on the market but it is also about how well best-of-breed technology can be brought together seamlessly and efficiently," said Dr Kuno van der Post, senior vice president business development. "Our partner centric approach is clearly resonating with the market place."

Supporting Information

About OmniComm Systems
OmniComm Systems is a leading strategic software solutions provider to the life sciences industry. OmniComm Systems is dedicated to helping the world's pharmaceutical; biotechnology; contract research organizations; diagnostic and device firms; and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,000 clinical trials. For more information, visit www.omnicomm.com.

Safe Harbor Disclaimer
Statements made by OmniComm Systems included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Trademarks
OmniComm, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.

More Stories By Marketwired .

Copyright Ā© 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.